Introduction
============

The incidence of surgical site infection (SSI) after spinal surgery ranges from 2 to 12%, depending on diagnosis, surgical approach, use of spinal instrumentation, and the complexity of the procedure [@B1]-[@B4].

SSI is a devastating complication that leads to prolonged treatment, with the need for subsequent reoperations and substantially increased overall health care costs. Moreover, SSI after instrumented spinal surgery is associated with higher rates of morbidity and mortality, and has a negative impact on functional clinical outcome [@B5]-[@B7].

There is no generally established treatment protocol for the management of deep SSI after instrumented spinal surgery. As we know from SSI after general fracture management with osteosynthesis, instrumentation is preferably left *in situ* as preservation of stability is crucial to allow for bony union while the infection is managed. Likewise, in spinal fusion, as long as bony union has not occurred, stable instrumentation material should be left *in situ* in order to prevent loss of correction or development of pseudarthrosis due to mechanical instability [@B8], [@B9]. After bony consolidation, the instrumentation can be removed if necessary in a second stage for complete cure of the infection [@B10].

Gentamicin impregnated carriers
-------------------------------

Polymethylmethacrylate (PMMA) or bone cement is able to release admixed powdery substances if these are soluble in water and heat stable during polymerization [@B11]. Buchholz admixed four heat stable antibiotic powders with bone cement and found that, except for tetracycline, the antibiotics indeed were released by a diffusion process for at least 2 weeks in a bactericidal concentration[@B11]. Subsequently, many handmade and commercially made combinations of antibiotics and bone cements were tested, of which gentamicin in combination with Palacos bone cement provided the best antibiotic release after implantation and best stability during polymerization.[@B12]-[@B14]

Gentamicin is very suitable for prevention or treatment of orthopedic infections since it exhibits a broad antibacterial spectrum including gram-positive and gram-negative germs, and a good bactericidal effect in low concentrations with a low rate of resistances development [@B15].

Gentamicin-impregnated bone cement was first introduced to prevent SSI after cemented implantation of joint arthroplasties[@B16]. Once on the market, it was also used to treat osteomyelitis by filling bone cavities after debridement. Because small beads of bone cement mixed with antibiotics were proven to be more effective, non-absorbable gentamicin impregnated PMMA beads (Septopal®) were commercially produced for local antibiotic treatment of infections, by admixing gentamicin to the liquid monomer and polymer powder, in combination with glycine as a filler to promote the gentamicin release [@B17].

In view of the successful treatment with these non-absorbable drug carriers, endeavours were made to develop absorbable materials that no longer needed removal. [@B18] Because collagen carriers are fully absorbed, gentamicin-collagen products can be used in one-step surgical procedures.

Pharmacokinetic release models have shown that the release of gentamicin from collagen fleeces is more rapid and less longstanding as compared to PMMA-beads [@B19]. Both carriers have shown a high local gentamicin concentration without toxic concentrations in the blood [@B19], [@B20].

Although commonly used in prosthetic joint infections (PJI) and osteomyelitis [@B21]-[@B23], the use of antibiotic loaded carriers in SSI after instrumented spinal fusion has not been widely reported [@B8], [@B20]-[@B24]. Because of good results in the use of gentamicin PMMA-beads or fleeces in the treatment of prosthetic joint infections [@B22], [@B23] we incorporated local gentamicin in the treatment of SSI after instrumented spinal fusion.

The aim of this study was to assess the treatment results after the use of a local gentamicin impregnated carriers, supplementary to operative debridement and administration of systemic antibiotics for SSI without union after instrumented spinal fusion, with an in-depth analysis of failed cases.

Material and methods
====================

This is a retrospective case-series analysis of all non-union, deep SSI patients after instrumented thoracolumbar spinal fusion procedures that had been performed in the Department of Orthopedics of the Maastricht University Medical Centre, a secondary and tertiary academic referral center for spinal pathology and for orthopaedic infections, from January 1999 up to December 2015.

Diagnosis
---------

The diagnosis of surgical site infection was based on criteria as described by the CDC (Centre for Disease Control and prevention) [@B25] and the Dutch national PREZIES network (*prevention of hospital infections through surveillance*) [@B26]. According to these criteria, a SSI was considered to be deep if it presented at the site of the operation with involvement of subfascial tissue [@B25].

Patients
--------

We diagnosed 62 (6,9%) deep surgical site infections (30 female, 32 male) out of 898 instrumented spinal surgery procedures (14 anterior approach, 884 posterior approach). 14 patients (4 female, 10 male) with an SSI were excluded from analysis: One patient had been treated for spondylodiscitis as the index operation, two patients did not receive treatment for SSI because of terminal illness and one patient was excluded because of loss to follow up. 10 patients had a late SSI with bony union of the spondylodesis. These 10 union SSI were all successfully treated with removal of the instrumentation and with additional local antibiotic administration in 2 patients. We included 48 patients (47 after posterior instrumented spinal fusion and 1 after anterior instrumented spinal fusion).

Treatment protocol
------------------

Deep infections of instrumented spinal fusion without bony consolidation, and without signs of implant loosening were treated by surgical debridement, systemic antibiotics, irrigation and implant retention (DAIR), in combination with application of antibiotics loaded carriers (gentamicin PMMA-beads or fleeces).

In case of instrumentation loosening and an unstable spine, new instrumentation was inserted for re-stabilisation. (Figure [1](#F1){ref-type="fig"})

The procedure consisted of debridement with removal of loose bone graft material, pulsed lavage with at least 3 litres of Ringer lactate and either retention, removal or re-stabilisation of the instrumentation depending on the stability of the instrumentation and spine. The patients were treated with systemic and local antibiotic therapy. As local antibiotic carrier we preferably used gentamicin PMMA beads with a diameter of 7 mm, containing 7.5 mg gentamicin sulphate, in chains of 30 or 60 beads (Septopal^®^, Merck GmbH, Darmstadt, Germany; Biomet GmbH, Berlin, Germany). We packed as many beads in the infected tissues as tensionless wound closure would allow in order to create a high local gentamicin concentration. Wounds were fully closed and the gentamycin beads were removed in a second procedure 2 weeks later.

Multiple tissue samples were taken for bacteriological cultures right before the administration of systemic antibiotics. The samples were cultured in the microbiology laboratory for at least 2 weeks in order to also detect slow growing microorganisms. The minimal inhibitory concentration (MIC) value for gentamicin of the specific bacteria strain was then determined.

If infection signs had not resolved, the gentamicin beads were removed, a new debridement was performed, and new beads were left behind during a second procedure 2 weeks later.

In case of very mild intraoperative infection signs, one debridement was considered to be enough and only gentamicin collagen fleeces were used as local gentamicin impregnated antibiotic carrier. Gentamicin collagen fleeces (Septocoll^®^, containing 116 mg gentamicin sulphate and 350 mg gentamicin crobephate in 320 mg equine collagen fleece with a size of 10x8 cm; Merck GmbH, Darmstadt, Germany; Biomet GmbH, Berlin, Germany) were applied before closing the wound, to prolong the period with local antibiotics and obviate the need for removal of the beads in another operation.

Spinal instrumentation was removed if, infection persisted according to clinical and laboratory parameters despite one or more treatment periods of 2 weeks with gentamicin beads. In case of instability because of non-union as determined intraoperatively by visible motion across the fused segment(s) and the absence of bony continuity on inspection, the spine was restabilized directly with renewed instrumentation [@B27], [@B28]. The infection treatment was then continued with the local application of gentamicin PMMA beads and intravenous administration of antibiotics.

Systemic antibiotics
--------------------

The surgical treatment was combined with high dosed systemic antibiotics, usually for a period of approximately 3 months, including a minimum of two weeks intravenous administration during hospitalization and continued oral administration after discharge from the hospital. The choice and exact duration of the systemic antibiotic treatment was decided on an individual basis and based on antibiotic resistance pattern of the causative bacteria by consultation of a microbiologist specialized in orthopaedic infections.

Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell counts (WBC) were measured twice a week during hospitalisation and at all outpatient control visits for monitoring of infection healing. We considered these parameters as normal when CRP and WBC counts were within the normal range (CRP \<10 mg/L; WBC\<10,000 cells/mcL) at 2 subsequent outpatient control visits, and the ESR was decreased to less than 30 mm/h in patients without systemic disease and cessation of systemic antibiotic treatment.

Outcome
-------

The treatment was considered successful when at follow up the infection was eradicated (normalized inflammatory blood markers and no clinical signs of infection) with a stable spine by instrumentation or by osseous fusion. Failure was diagnosed if the infection was not eradicated.

The subjective outcome (disabling back pain or leg pain with limitations in activities of daily living (ADL)) were noted as "yes" or "no" at the end of the follow-up at the outpatient clinic.

The follow-up period started at the date of the first operation for infection, and ended on the date of the last outpatient clinic visit, the last contact with the family doctor or the date of death. The minimum follow up was 1.5 year or shorter in case of death, either related or not to the SSI.

Statistical analysis
--------------------

Patient characteristics (gender, age, BMI, smoking status, comorbidities, ASA-score, medication, trauma, radiation therapy, blood values, revision surgery, interval between primary surgery and infection treatment, antibiotic use and MIC genta) and operation variables (primary indication, combination surgery with a second incision, fused levels, anatomical levels, graft use, cage use, dural tear, micro-organism and soft tissue condition) were presented as either median with total range, or as mean with standard deviation (SD).

Additionally, the odds ratios (OR) with 95% confidence intervals (CI) were calculated for all patients\' characteristics and risk factors for poor treatment outcome. The Mann Whitney U test was used to analyse differences of continuous variables between successfully treated patients and failures. SPSS (version 17.0) was used for all statistical calculations.

Results
=======

48 patients with a deep SSI without bony union were treated, of which 42 (87.5%) were treated successfully. Recurrence of infection occurred after more than 2 years in 2 patients. Four patients died during infection treatment because of sepsis (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

37 of 48 patients were treated with debridement, retention of the stable instrumentation (DAIR), and local antibiotics: 33 of these 37 were treated successfully, while 4 failed.

8 of the 48 patients were treated with DAIR after restabilization of loose instrumentation of which 3 without local antibiotics, because there were minimal signs of infection intraoperatively.

Instrumentation was removed without spinal restabilization in 3 of the 48 patients, as the lumbar spine was considered stable after instrumentation removal. These 3 cases were all treated with gentamicin PMMA beads. One of these patients required anterior restabilization in a second stage after 2 periods of treatment with gentamicin PMMA beads. (Figure [1](#F1){ref-type="fig"})

6 of the 48 patients were treated with only one debridement, and 24 were treated with 2 debridements, whereas 15 needed 3 debridements and only 3 patients needed 4 debridements of the wound.

The median time of systemic intravenous antibiotic treatment was 41 (3-95) days, followed by oral treatment for another 43 (0-196) days. The median total antibiotic therapy time was 84 (6-251) days. Oral antibiotic treatment at the outpatient clinic was stopped when clinical and laboratory parameters were considered as normal. *Staphylococcus aureus* was found as the most frequent (24/48) causative microorganism (Table [2](#T2){ref-type="table"}). There was no significant difference with respect to causative micro-organism between the failed and the successfully treated patients. No relation could be found between the MIC value for gentamicin of the causative bacteria and the success rate of the infection treatment. (Table [3](#T3){ref-type="table"})

5 of the 6 patients (83%) in whom the infection treatment failed had an ASA-score \>2 compared to only 12 of 42 (29%) in the population with a successful treatment.

There were no other isolated patient characteristics or operation-related variables that differed significantly between the 6 patients in whom the infection treatment failed and the 42 successfully treated patients. (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"})

At the end of follow-up, 5 patients (10.4%) complained of residual disabling back pain with limitations in ADL, 2 patients (4.2%) complained of persisting disabling leg pain with limitations in ADL, and 3 patients (6.3%) had residual disabling back and leg pain with limitations in ADL.

In summary, 87.5% (42/48) of all patients with a SSI and non-union after an instrumented spinal procedure where treated successfully with a treatment regimen consisting of systemic antibiotics and repetitive surgical debridement supplemented with local gentamicin releasing carriers. 8% (4/48) died during infection treatment because of sepsis and in 4% (2/48) recurrence of infection occurred after more than 2 years.

Discussion
==========

The present study analyzed treatment of SSI and non-union in patients who underwent instrumented fusion of the thoracolumbar spine, with the use of gentamicin impregnated carriers. 42 of the 48 (87.5%) patients showed successful resolution of infection with stable spinal fusion at the end of treatment, without recurrence of infection after a minimum of 1.5 years follow-up.

Although direct comparison with results from other studies in literature is difficult due to the heterogeneity of patient populations, the success rate of treatment in the present study appears to be quite high., Chen et al. reported an implant salvage success rate of 80.4% (41 in 51 patients) with repeated debridements (mean 1.7), systemic antibiotics, with adjunctive antibiotic-impregnated PMMA beads in 20 patients after a 2-year follow-up in patients with SSI after posterior spinal instrumentation.

In 8 of the 41 (19.5%) successfully treated cases, solid fusion was not achieved. Furthermore, only 2 out of 10 patients (20%) who underwent debridement with implant removal showed stable fusion. Unfortunately, the success rate of a subgroup of 20 patients who were treated with antibiotic loaded PMMA beads was not reported separately [@B29].

Glassman et al. treated 22 patients with SSI after instrumented spinal fusion with multiple debridements (mean 4.7), retention of the instrumentation, and antibiotic (tobramycin and vancomycin) impregnated PMMA beads. No patient showed recurrence of wound infection. Fusion was apparently solid in 14 patients, probable in four patients and nonunion occurred in one patient [@B30].

Compared to previous studies in which antibiotic carriers have not been used, the present study shows a favourable success rate. Kowalski et al. reported a success rate of 71% in 28 early onset spinal implant infections with retention of instrumentation, and 84% in 32 late onset spinal implant infections with operative debridement and removal of instrumentation [@B31]. Collins et al. reported a cure rate of 40% in 15 acute infections following instrumented spinal fusion with long-term (systemic) antibiotics and debridement with retention of the instrumentation [@B6]. The lower eradication rates observed in these studies clearly illustrate the added value of local antibiotic carriers in infection treatment after instrumented spine surgery in our opinion.

Kim et al. treated 20 patients with SSI between 1 and 5 months after instrumented spinal surgery with implant removal and wide debridement to clear the infection, despite the risk of disc space collapse and loss of normal lordosis. The infection was eradicated in all 20 patients after a minimum follow up of 2 years, but instability and/or pseudarthrosis at the fused segments was observed in 14 patients, thus resulting in a poor clinical outcome [@B32].

Several other supplemental procedures have been reported in the treatment of SSI after instrumented spinal fusion aside from the use of antibiotic impregnated PMMA beads, such as continuous suction irrigation, vacuum-assisted wound closure, or local tissue flap coverage. These studies are difficult to compare, because of the different treatment procedures. However the success rate of the present study is in the higher range of the success rates reported for these alternative supplemental procedures. Rohmiller et al. treated 28 patients with post-operative spinal infection with one operative session consisting of incision, drainage and closed suction irrigation. 75% of infections were resolved without recurrence after an average follow-up of 22.3 months. [@B33]

Mehbod et al. achieved a clean closed wound after an average follow-up of 10 months (6-24 months) in all of 20 patients with SSI after spinal fusion, treated with an average of 1.8 (1-8) debridements prior to a vacuum-assisted wound closure procedure, and an ultimate VAC removal procedure in which the wound was closed over drains[@B34]. Labler et al. needed to exchange or remove the instrumentation in 12 of 13 infections after instrumented spinal surgery treated with vacuum assisted closure of the wound (15-40 months follow-up). One patient developed a recurrence infection at follow-up [@B35]. Sierra-Hoffman et al. reported a cure rate of 89% for early onset instrumented spinal infection in 19 patients by debridement with retention of the instrumentation, drainage and packed open with antibiotic solution soaked gauze and loose retention sutures. All patients returned to the operating room for follow-up debridement and closure over drains after 2-3 days, followed by systemic antibiotic administration. They noted a cure rate of 100% with no relapses for at least 3 years after therapy was reported in 7 late onset infections with removal of the instrumentation and 1 or 2 debridements [@B4].

In this study, a mean number of 2.3 (1-4) operations were needed including the removal of the PMMA beads, mostly a minor operation. Picada et al. reported that one-third of 26 patients required four or more debridements before obtaining a clean wound for closure [@B36]. Mehbod et al. reported a mean number of 3.25 (3-10) visits to the operating room to obtain a closed wound with vacuum-assisted wound closure in 20 patients [@B34].

In the present study 16.7% of the patients complained of residual disabling back pain at the end of the follow up, and 27.1% patients in total experienced limitations in activities of daily living because of residual back and/or leg pain. Similar to most studies in literature, our patients showed a less satisfactory outcome after instrumented spinal fusion with SSI compared with control groups without infection. [@B29], [@B37], [@B38]

We found *Staphylococcus aureus* (*S. aureus*) to be the most frequent (24/48) causative microorganism of SSI. This is comparable to literature [@B6], [@B29], [@B33], [@B39]. International literature reports suggest an increasing prevalence of MRSA [@B8], [@B32], but MRSA was not cultured in our patients. This may be the result of the strict MRSA policy in the Netherlands [@B40].

Those patients with a failure of infection treatment had a significantly higher ASA score preoperatively as compared to the patients with a successful treatment. This difference is similar to findings in the literature on the infection treatment of hip and knee prosthesis infections [@B22], [@B23]. No firm conclusion can be drawn due to of lack of statistical power.

The present study has several limitations. The study design is retrospective, and although the number of 48 patients was adequate as compared to other studies in literature, there were only 6/58 failures of treatment. The heterogeneity of patient and operation-related characteristics (time to infection treatment, indication of primary surgery, number of fused levels) in this study makes it hard to interpret outcome. A comparison to literature is even more difficult because of differences in treatment, definitions for outcome, patient characteristics, differences in surgical indications, and prevalence of micro-organisms. Another limitation was that the functional outcome was assessed by retrospective analysis of the files at the outpatient clinic.

All currently available clinical evidence regarding the treatment of postoperative infections after instrumented spinal surgery is based on uncontrolled retrospective studies. It is hard to conduct randomized controlled trials, as it would the cooperation of many centres in this field would be required due to the low infection rates and heterogeneity of patient populations.

A valuable alternative for future research would be setting up national and international registries to compare data of diagnosis, operations, comorbidity, and treatment of the infection and outcome variables in large patient populations. Although of lower internal validity as compared to RCT\'s, evidence of high external validity could be obtained in this way as the included patients would genuinely reflect daily clinical practice.

Conclusion and Clinical Relevance
=================================

Debridement and retention of instrumentation in combination with systemic antibiotics and the addition of local antibiotics (gentamicin impregnated PMMA beads or fleeces) results in successful treatment for SSI and non-union after instrumented spinal fusion.

![**Treatment algorithm of deep surgical site infection after instrumented spinal fusion.** ^\*^ 45/48 infections were treated with debridement of the wound and a local gentamicin carrier (gentamicin fleeces in 3 SSI and gentamicin PMMA beads in 42 SSI) and 3/48 were treated without local gentamicin treatment because of very mild signs of a deep infection during operation. ^β^ 3/4 failures died sepsis-related during infection treatment. One failure presented with a recurrent infection with the same initial micro-organism (*Staphylococcus aureus*) that was successfully treated with removal of the instrumentation and local gentamicin PMMA beads. ^α^ 1 failure died during infection treatment because of sepsis. ^\#^ 1 failure was a recurrence of infection of the anterior instrumentation that occurred more than 3 years after the secondary restabilization. This patient died during the second infection treatment because of a poor health condition (terminal metastatic renal cancer).](jbjiv03p0094g001){#F1}

![Kaplan-Meier survival curve that represents the proportion of all patients free of infection after treatment for deep SSI after instrumented spinal fusion.](jbjiv03p0094g002){#F2}

###### 

Details of the patients

  Diagnosis                              pathogen         Interval (days)   Debride-ments   FU     Outcome   Treatment                                                       Subjective outcome
  -------------------------------------- ---------------- ----------------- --------------- ------ --------- --------------------------------------------------------------- ------------------------------------------
  Fracture with threatened myelum        S. viridans      1                 1               1062   Success   Debridement, restabilization, no local AB                       Back pain & disabilities in ADLs
  Scoliosis (degenerative)               E. Coli          8                 2               962    Success   DIAR + fleeces                                                  Back pain, no disabilities in ADLs
  Degenerative spondylolysis             E. coli          9                 3               1159   Success   DIAR + beads                                                    Back pain, no disabilities in ADLs
  Failed previous spine surgery          S. Aureus        9                 3               1195   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  HNP with threatened myelum             S. Aureus        9                 3               882    Success   DIAR + beads                                                    Disabilities in ADLs without pain
  RIP with threatened myelum             E. Coli          10                2               875    Success   Debribement, restabilization + beads                            Leg pain & disabilities in ADLs
  RIP with threatened myelum             mixed flora      10                2               1277   Failure   Removal implants + beads, restabilization in second procedure   No pain or disabilities in ADLs
  Failed previous spine surgery          mixed flora      11                1               371    Success   DIAR, no local AB                                               No pain or disabilities in ADLs
  Fracture with threatened myelum        E. cloacae       12                2               1185   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         mixed flora      12                3               1402   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Fracture without threatened myelum     S. Aureus        12                2               733    Success   Debribement, restabilization + beads                            Back pain, no disabilities in ADLs
  Spinal stenosis                        S. Aureus        13                3               406    Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Fracture without threatened myelum     E. coli          13                2               884    Success   DIAR + beads                                                    Disabilities in ADLs without pain
  Fracture without threatened myelum     S. Aureus        13                2               1092   Failure   DIAR + beads                                                    Back pain, no disabilities in ADLs
  Degenerative spondylolisthesis         E. Coli          13                1               1106   Success   DIAR + fleeces                                                  No pain or disabilities in ADLs
  Degenerative spondylolisthesis         E. cloacae       14                2               519    Success   DIAR + beads                                                    Back & leg pain & disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        14                4               1163   Success   DIAR + beads                                                    Back & leg pain, no disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        15                3               251    Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        15                3               1007   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. pyogenes      15                1               1334   Success   DIAR + beads                                                    Back pain & disabilities in ADLs
  Spinal stenosis                        S. Aureus        15                2               1483   Success   DIAR + beads                                                    Back pain & disabilities in ADLs
  Lytic spondylolisthesis                mixed flora      16                2               1037   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        16                3               1039   Success   DIAR + beads                                                    Back pain, no disabilities in ADLs
  Pseudoartrosis                         S. Aureus        16                1               1219   Success   Removal implants + beads                                        No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. mitis         17                3               762    Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Scoliosis (degenerative)               CNS              17                2               854    Success   DIAR + beads                                                    Leg pain & disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        17                3               745    Success   Removal implants + beads                                        Back & leg pain & disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        18                1               8      Failure   DIAR + beads                                                    Dead
  Degenerative spondylolisthesis         mixed flora      18                2               1466   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         CNS              19                3               976    Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Fracture without threatened myelum     S. Aureus        20                1               15     Failure   DIAR + beads                                                    Dead
  Fracture with threatened myelum        E. coli          20                2               275    Success   DIAR + beads                                                    Disabilities in ADLs without pain
  Degenerative spondylolisthesis         mixed flora      20                4               741    Success   Debribement, restabilization + beads                            Back & leg pain & disabilities in ADLs
  Fracture without threatened myelum     S. Aureus        21                2               777    Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Spinal stenosis                        S. Aureus        21                3               1065   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Fracture without threatened myelum     S. Aureus        21                2               5017   Success   Debribement, restabilization + beads                            Back pain & disabilities in ADLs
  Fracture with threatened myelum        E. Coli          22                1               1474   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        23                2               1187   Success   DIAR + beads                                                    No pain or disabilities in ADLs
  Spinal stenosis                        S. Aureus        30                1               2770   Success   DIAR + beads                                                    Back pain, no disabilities in ADLs
  RIP with threatened myelum             S. Aureus        31                1               42     Failure   DIAR + beads                                                    Dead
  RIP with threatened myelum             CNS              33                2               583    Success   Debribement, restabilization + beads                            No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        48                2               62     Failure   Debribement, restabilization + beads                            Dead
  RIP with threatened myelum             S. Aureus        63                2               191    Success   DIAR + beads                                                    Back pain, no disabilities in ADLs
  Degenerative spondylolisthesis         G. elegans       66                1               458    Success   DIAR + beads                                                    Leg pain, no disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        66                4               848    Success   DIAR + fleeces                                                  Back pain & disabilities in ADLs
  Fracture without threatened myelum     P. acnes         90                1               1112   Success   DIAR, no local AB                                               No pain or disabilities in ADLs
  Degenerative spondylolisthesis         S. Aureus        141               2               378    Success   Debribement, restabilization + beads                            No pain or disabilities in ADLs
  Fracture without threatened myelum     S. pneumoniae    186               2               1080   Success   DIAR + beads                                                    Back pain, no disabilities in ADLs
  Failed previous spine surgery          negative         265               1               1035   Success   Removal implants + beads                                        Back pain & disabilities in ADLs
  Fracture without threatened myelum     P. aeruginosa    308               1               1336   Success   Removal implants, no local AB                                   No pain or disabilities in ADLs
  Failed previous spine surgery          negative         345               2               2920   Success   Removal implants + beads                                        Back & leg pain & disabilities in ADLs
  Fracture without threatened myelum     S. intermedius   402               2               1058   Success   Removal implants, no local AB                                   Back pain & disabilities in ADLs
  Failed previous spine surgery          P. acnes         525               1               2105   Success   Removal implants, no local AB                                   Back pain & disabilities in ADLs
  Fracture without threatened myelum     P. acnes         531               1               1157   Success   Removal implants, no local AB                                   No pain or disabilities in ADLs
  Degenerative disc disease/discopathy   P. acnes         691               1               1550   Success   Removal implants, no local AB                                   Back pain & disabilities in ADLs
  Fracture with threatened myelum        P. acnes         934               1               811    Success   Removal implants, no local AB                                   No pain or disabilities in ADLs
  Scoliosis, idiopathic                  S. Aureus        2723              1               756    Success   Removal implants, no local AB                                   No pain or disabilities in ADLs
  Fracture with threatened myelum        CNS              3292              1               1862   Success   Removal implants, no local AB                                   No pain or disabilities in ADLs

###### 

Operation related variables

  ---------------------------------------------------------------------------------------------------------------------------------------
  Operation-related variable           Overall       Successful (42)\      Failed (6)\           Odds-ratio   95%Cl           *p*-value
                                                     Infection treatment   Infection treatment                                
  ------------------------------------ ------------- --------------------- --------------------- ------------ --------------- -----------
  **Operation-indication**                                                                                                    

  Fracture                             12 (25.0%)    10 (23.8%)            2 (33.3%)             0.625        0.099-3.935     0.616

  Degenerative spine-disorders         23 (47.9%)    21 (50.0%)            2 (33.3%)             2.000        0.329-12.123    0.451

  Spinal stenosis                      4 (8.3%)      4 (9.5%)              0                     1.520        0.073-31.693    0.787

  Spinal metastasis                    5 (10.4%)     3 (7.1%)              2 (33.3%)             0.154        0.020-1.212     0.076

  Failed previous spine surgery        2 (4.2%)      2 (4.8%)              0                     0.803        0.035-18.677    0.891

  Other                                3 (6.3%)      3 (7.1%)              0                     1.152        0.053-24.993    0.928

  Combined surgery (second incision)   3 (6.3%)      3 (7.1%)              0                     1.152        0.053-24.993    0.928

  **Levels fused**                                                                                                            

  Number                               2.6 (1 - 9)   2.6 (1 - 9)           3.2 (1 - 6)           1.042        0.683 - 1.590   0.848

  **Anatomical levels**                                                                                                       

  Thoracic                             7 (14.6%)     5 (11.9%)             2 (33.3%)             0.270        0.039-1.876     0.186

  Thoracolumbar                        8 (16.7%)     6 (14.3%)             2 (33.3%)             0.333        0.050-2.239     0.258

  Lumbar                               19 (39.6%)    18 (42.9%)            1 (1.7%)              3.750        0.402-34.957    0.246

  Lumbosacral                          13 (27.1%)    12 (28.6%)            1 (1.7%)              2.000        0.211-18.957    0.546

  Thoracic, lumbar and sacral          1 (2.1%)      1 (2.4%)              0                     0.470        0.017-12.813    0.654

  Bone graft                           41 (85.4%)    37 (88.1%)            4 (66.7%)             3.700        0.533-25.679    0.186

  Other than Autograft                 10 (20.8%)    7 (16.7%)             3 (50.0%)             0.200        0.033-1.203     0.079

  Cage used                            33 (68.8%)    31 (73.8%)            2 (33.3%)             5.636        0.903-35.189    0.064

  Dural tear                           7 (14.6%)     6 (14.3%)             1 (16.7%)             0.833        0.082-8.433     0.877

  **Micro-organism**                                                                                                          

  Staphylococcus Aureus                24 (50.0%)    19 (45.2%)            5 (83.3%)             0,165        0,018-1,539     0,114

  Proprionibacterium acnes (spp.)      1 (2.1%)      1 (2.4%)              0                     0.470        0.017-12.813    0.654

  Coagulase negative staphylococcus    3 (6.3%)      3 (7.1%)              0                     1.152        0.053-24.993    0.928

  Enterobacter species                 9 (18.8%)     9 (21.4%)             0                     3.687        0.190-71.525    0.389

  Streptococci species                 5 (10.4%)     5 (11.9%)             0                     1.907        0.094-38.778    0.675

  Polymicrobial                        6 (12.5%)     5 (11.9%)             1 (16.7%)             0.676        0.065-7.024     0.743

  **Soft tissue condition**                                                                                                   

  Intact                               2 (4.2%)      1 (2.4%)              1 (16.7%)             0.122        0.007-2.268     0.158

  Open (wet)                           43 (89.6%)    38 (90.5%)            5 (83.3%)             1.900        0.176-20.560    0.597

  Abscess/ fistula                     3 (6.3%)      3 (7.1%)              0                     1.152        0.053-24.993    0.928
  ---------------------------------------------------------------------------------------------------------------------------------------

###### 

Patient related variables

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient-related variables                       Overall (58)         Successful (52)\      Failed (6)\           Odds-ratio   95%Cl          *p*-value
                                                                       infection treatment   infection treatment                               
  ----------------------------------------------- -------------------- --------------------- --------------------- ------------ -------------- -----------
  Man                                             22 (45.8%)           19 (45.2%)            3 (50.0%)             0.826        0.149-4.576    0.827

  Woman                                           26 (46.6%)           23 (46.2%)            3 (50.0%)             1.211        0.219-6.705    0.827

  Age                                             58.3 (19-83)         56.3 (19 - 83)        65.1 (37 - 80)                                    0.177\*

  BMI                                             28.2 (17.7 - 41.3)   28.3 (17.7 - 41.3)    28.1 (22.4 - 34.7)                                0.327\*

  Obesity (BMI \> 30)                             19 (39.6%)           18 (42.9%)            1 (16.7%)             3.750        0.402-34.957   0.246

  Smoking                                         23 (47.1%)           21 (50.0%)            2 (33.3%)             2.000        0.330-12.123   0.451

  Comorbidities                                                                                                                                

  Diabetes                                        6 (12.5%)            5 (11.9%)             1 (16.7%)             0.676        0.065-7.024    0.743

  Pulmonary disease                               14 (29.2%)           13 (31.0%)            1 (16.7%)             2.241        0.238-21.150   0.481

  Rheumatic disease                               8 (16.7%)            7 (16.7%)             1 (16.7%)             1.000        0.101-9.928    1.000

  Cardiac disease                                 11 (22.9%)           9 (21.4%)             2 (33.3%)             0.546        0.086-3.471    0.521

  Malignancy (active)                             6 (12.5%)            4 (9.5%)              2 (33.3%)             0.211        0.029-1.533    0.124

  ASA I                                           9 (18.8%)            9 (21.4%)             0                     3.687        0.190-71.525   0.389

  ASA II                                          21 (43.8%)           20 (47.6%)            1 (16.7%)             4.546        0.488-42.307   0.183

  ASA III                                         17 (35.4%)           12 (28.6%)            5 (83.3%)             0.080        0.008-0.758    0.028

  Medication                                                                                                                                   

  Use Steroid                                     8 (16.7%)            6 (14.3%)             2 (33.3%)             0.333        0.050-2.239    0.258

  Use of immunosuppressive                        5 (10.4%)            3 (7.1%)              2 (33.3%)             0.154        0.020-1.212    0.076

  Trauma patient                                  7 (14.6%)            5 (11.9%)             2 (33.3%)             0.270        0.039-1.876    0.186

  Polytraumatic injury                            2 (4.2%)             2 (4.8%)              0                     0.803        0.035-18.677   0.891

  UCI admission                                   3 (6.3%)             2 (4.8%)              1 (16.7%)             0.250        0.019-3.280    0.291

  Radiation therapy after initial spine surgery   5 (10.4%)            3 (7.1%)              2 (33.3%)             0.154        0.020-1.212    0.076

  Blood values preop.                                                                                                                          

  CRP                                             169.3 (6 - 584)      152.6 (6 - 584)       298.5 (209 - 414)                                 0,412\*

  ESR                                             57.7 (10 - 120)      55.7 (10 - 112)       75.2 (47 - 120)                                   0,617\*

  Leucocytes                                      16.1 (1 - 87)        16.5 (1 - 87)         12.8 (6.9 - 16.4)                                 0.904\*

  Temperature preop.                              37.8 (36.4 - 40.0)   37.8 (36.4 - 40.0)    38.1 (36.4 - 39.5)                                0.912\*

  Primary                                         35 (72.9%)           30 (76.2%)            5 (83.3%)             0.500        0.053-4.739    0.546

  Revision                                        13 (27.1%)           12 (23.8%)            1 (16.7%)             2.000        0.211-18.957   0.546

  Interval surgery to start infection symptoms    33 (1 - 186)         34 (1 - 186)          24 (10 - 49)                                      0.667\*

  Preop. use of AB                                28 (58.3%)           24 (57.1%)            4 (66.7%)             0.667        0.110-4.050    0.660

  Postop. duration AB iv                          38.0 (6 - 95)        39.4 (8 - 95)         29.3 (6 - 59)                                     0.275\*

  Postop. duration AB oral                        48.6 (0 - 196)       47.7 (14 - 133)       55.0 (0 - 196)                                    0.412\*

  Postop. duration AB total                       78.7 (6 - 251)       79.3 (15 - 201)       75.2 (6 - 251)                                    0.242\*

  MIC-genta                                       27.5 (0.50 - 64)     30.6 (0.5 - 64)       1.5 (0.5 - 2.0)                                   0.509\*

  Total number of gentamicin-beads                123.3 (0 - 240)      121.4 (0 - 240)       142.5 (120 - 180)                                 0.412\*
  --------------------------------------------------------------------------------------------------------------------------------------------------------

\*= Mann Withney U test

[^1]: Competing Interests: The authors have declared that no competing interest exists.
